Clinical and Physiological Characterization of Elevated Plasma Glucagon-Like Peptide-1 Levels (Hyperglipemia) in a Dipeptidyl Peptidase IV Mutation Carrier

The clinical application of dipeptidyl peptidase IV inhibitors (DPP4i) increasing active glucagon-like peptide-1 (AGLP-1) levels has been linked to pancreatitis, pancreatic tumors, and cardiovascular events. However, DPP4 mutations in humans or the long-term outcomes of high glucagon-like peptide-1...

Cijeli opis

Bibliografski detalji

Glavni autori:	Dandan Zhao, Shaoqian Zhao, Xiao Wang, Mingbo Su, Wen Liu, Qinyun Ma, Jie Hong, Weiqiong Gu, Jingya Li, Ruixin Liu, Guang Ning, Jiqiu Wang, Yifei Zhang
Format:	Artigo
Jezik:	Inglês
Izdano:	Frontiers Media S.A. 2018-03-01
Serija:	Frontiers in Endocrinology
Teme:	dipeptidyl peptidase IV glucagon-like peptide-1 β-cell function type 2 diabetes incretin effect
Online pristup:	http://journal.frontiersin.org/article/10.3389/fendo.2018.00062/full
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!